Comparative Pharmacology
Head-to-head clinical analysis: GILDESS FE 1 20 versus TRI ESTARYLLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GILDESS FE 1 20 versus TRI ESTARYLLA.
GILDESS FE 1/20 vs TRI-ESTARYLLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release; norethindrone induces progestational changes in endometrium and cervical mucus, preventing ovulation and fertilization.
Combination hormonal contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Drospirenone is a spironolactone analogue with anti-mineralocorticoid and antiandrogenic activity, also suppressing ovulation and increasing cervical mucus viscosity.
One tablet orally once daily for 21 days followed by 7 placebo tablets per 28-day cycle.
One tablet (ethinyl estradiol 0.03 mg / norgestimate 0.18-0.215-0.25 mg) orally once daily for 21 days followed by 7 placebo days.
None Documented
None Documented
Ethinyl estradiol: terminal half-life approximately 13 hours (range 10-15 h). Desogestrel: metabolized to etonogestrel; etonogestrel terminal half-life about 28 hours (range 20-40 h). Clinical context: steady-state reached within 7-10 days.
Terminal elimination half-life is 4-6 hours; clinical context: allows twice-daily dosing for stable blood levels.
Approximately 60-65% renal (as metabolites), 30-35% fecal (as metabolites and unchanged drug). Ethinyl estradiol and desogestrel metabolites are excreted primarily via urine and feces. Etonogestrel (active metabolite) is excreted mainly via feces (40%) and urine (32%).
Renal: approximately 60% as unchanged drug and metabolites; Biliary/fecal: approximately 40%, primarily as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive